Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease.
It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite.
Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 25 | -0.25 Decreased by -3.00% | -0.55 Increased by +55.05% |
| Mar 11, 25 | -0.37 Decreased by -138.22% | -0.31 Decreased by -18.35% |
| Nov 11, 24 | -0.32 Decreased by -900.00% | -0.50 Increased by +36.00% |
| Aug 5, 24 | -0.33 Decreased by -43.48% | -0.38 Increased by +13.16% |
| May 15, 24 | -0.24 Increased by +4.00% | -0.04 Decreased by -500.00% |
| Mar 13, 24 | 0.96 Increased by +74.55% | -0.10 Increased by +1.06 K% |
| Nov 13, 23 | 0.04 Increased by +112.12% | -0.03 Increased by +233.33% |
| Aug 10, 23 | -0.23 Increased by +73.56% | -0.34 Increased by +32.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 5.87 M Increased by +39.72% | -14.73 M Decreased by -16.28% | Decreased by -250.78% Increased by +16.78% |
| Dec 31, 24 | 9.36 M Decreased by -86.97% | -20.89 M Decreased by -140.80% | Decreased by -223.26% Decreased by -413.26% |
| Sep 30, 24 | 13.47 M Decreased by -47.12% | -17.15 M Decreased by -435.01% | Decreased by -127.31% Decreased by -911.82% |
| Jun 30, 24 | 6.02 M Increased by +663.58% | -17.86 M Decreased by -49.92% | Decreased by -296.86% Increased by +80.37% |
| Mar 31, 24 | 4.20 M Increased by +468.11% | -12.67 M Decreased by -2.96% | Decreased by -301.36% Increased by +81.88% |
| Dec 31, 23 | 71.83 M Increased by +55.13% | 51.19 M Increased by +91.22% | Increased by +71.27% Increased by +23.26% |
| Sep 30, 23 | 25.47 M Increased by +2.25 K% | -3.21 M Increased by +72.55% | Decreased by -12.58% Increased by +98.83% |
| Jun 30, 23 | 788.00 K Decreased by -12.05% | -11.91 M Increased by +58.46% | Decreased by -1.51 K% Increased by +52.77% |